VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO Immuno-Oncology 2022 | What does the future hold for LAG-3 as a novel target in melanoma?

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, describes the potential role of targeting LAG-3 in treating melanoma. LAG-3 will be crucial and developing doublet and triplet therapies and has been identified as a promising target in uveal melanoma, as well as a marker in T cell exhaustion. Dr Hamid additionally highlights advances in the development of CAR-T cells and bispecific antibodies. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter